SCHOTT TOPPAC® infuse - The next generation
CONTACT USThe next generation of infuse redefines efficiency, stability, and speed
Hospitals face a variety of challenges, from high drug waste caused by unclear packaging to manual tray preparation and storage issues. The limited shelf life of compound syringes, FDA restrictions on polypropylene (PP) syringes, and the risk of medical errors due to manual syringe preparation further complicate the situation. Pharmaceutical companies also struggle with stringent regulatory requirements that delay the development of combination products.A next-generation solution is essential to improving operational efficiency, ensuring long shelf-life efficacy, and speeding up time to market. Introducing SCHOTT TOPPAC® infuse — the next generation. Hello choice!
The next generation of stability
Prefilled syringes, such as SCHOTT TOPPAC® infuse, offer significant advantages when compared with manually prepared syringes with vials. They help reduce contamination and enhance patient safety by minimizing the need for manual preparation. This greatly lowers the risk of medication errors, contamination, and drug waste.-
Based on analysis by Schwarzenbach et al. (2013), using prefilled syringes can decrease the risk of contamination by 42.9% when compared with vials.
-
Based on analysis by Drain et al. (2003), using prefilled syringes can significantly reduce drug waste by 63% when compared with vials.
Based on analysis by Schwarzenbach et al. (2013), using prefilled syringes can decrease the risk of contamination by 42.9% when compared with vials.
FDA restrictions on PP syringes arise from their inability to maintain drug stability over time. The high-quality SCHOTT TOPPAC® infuse syringe is made of inert cyclic olefin copolymer (COC) and rubber components of the highest purity. The syringe also benefits from cross-linked silicone and an improved break loose and gliding force to enhance drug stability and extend shelf life. The syringe also provides excellent moisture and oxygen barriers, with additional functional labels available to further improve these barrier properties.
The next generation of efficiency
The next generation of SCHOTT TOPPAC® infuse polymer syringes features new caps and labels that cover the syringe shoulder to provide first-opening indication. An RFID chip can also be included in the label, enabling digital first-opening indication and medication inventory management. Based on their new design, SCHOTT TOPPAC® infuse polymer syringes are the baseline for blister-free packaging. These innovations enhance operational efficiency and reduce costs. Find out more about these new functionalities:
First-opening indication
Reduces drug waste and improves patient safety
Hospitals often struggle to maintain drug integrity as there is no clear indication of whether a syringe has been used or opened once it has been removed from its secondary packaging. This leads to increased drug waste.With a new cap and label, SCHOTT TOPPAC® infuse offers first-opening indication, while an optional RFID chip enables digital first-opening indication. This innovation minimizes drug waste after operation, as well as the risk of medication being compromised once it leaves the filling station.
Digital medication inventory
Increases efficiency and reduces errors during preparation
The manual preparation of anesthesia trays is not only time-consuming, but can lead to delays, while manual tagging and data entry increase the risk of errors. The integrated RFID chip in the SCHOTT TOPPAC® infuse label enables contactless data transfer, streamlining the preparation process. This improves medication inventory management and digitizes patient records, enhancing overall operational efficiency.Blister-free packaging
Minimizes waste and reduces space
Hospitals often have limited space for syringe storage, while pharmaceutical companies are under increasing pressure to reduce their CO2 footprint. The new SCHOTT TOPPAC® infuse polymer syringe is the baseline for blister-free packaging as it offers complete labelling – for example, oxygen or light protection. The new concept delivers 20% more syringes per container, which results in a 58% reduction in CO2 footprint, three times less storage space required, and an 80% decrease in plastic and packaging waste (based on 151,200 units of 5 ml SCHOTT TOPPAC® infuse syringes).First-opening indication
Digital medication inventory
Blister-free packaging
The next generation of speed
Since SCHOTT Pharma has over 20 years of experience and SCHOTT TOPPAC® is registered in more than 90 countries, we can simplify your registration process. Our design-driven development ensures simple validation and faster time-to-market, while our technical support and analytical services will guide you through your drug development journey.Trust SCHOTT TOPPAC® – the reliable choice for the long term. As a leader in the COC market, we serve over 100 commercial customers, with four blockbuster drugs using our syringes. Don’t risk delays in your drug launch—choose a proven product!
Say hello to your choice: SCHOTT TOPPAC® infuse – the next generation
Christoph Zauner
Head of Product Management Polymer Solutions